Evidence to Practice (@evi2prac) 's Twitter Profile
Evidence to Practice

@evi2prac

We bring new evidence from clinical trials to the clinical community via educational activities, enabling informed uptake of new treatments and best practice.

ID: 1036861111859965952

linkhttp://www.e2p.com.au calendar_today04-09-2018 06:18:47

205 Tweet

104 Takipçi

123 Takip Edilen

Evidence to Practice (@evi2prac) 's Twitter Profile Photo
Evidence to Practice
@evi2prac

3 years ago

ALL-HEART - Allopurinol added to usual care did not improve outcomes in patients aged over 60 years with IHD (but no gout) #ESCCongress

ALL-HEART - Allopurinol added to usual care did not improve outcomes in patients aged over 60 years with IHD (but no gout) #ESCCongress
NEJM (@nejm) 's Twitter Profile Photo
NEJM
@nejm

3 years ago

DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress nej.md/3PJ6Oir

DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress nej.md/3PJ6Oir
Evidence to Practice (@evi2prac) 's Twitter Profile Photo
Evidence to Practice
@evi2prac

3 years ago

The INVICTUS study showing that in RHD-AF, compared to rivaroxaban,VKAs have a lower mortality and reduced ischemic stroke without increasing the risk of major bleeding. VKAs should remain the standard of care in RHD-AF

The INVICTUS study showing that in RHD-AF, compared to rivaroxaban,VKAs have a lower mortality and reduced ischemic stroke without increasing the risk of major bleeding. VKAs should remain the standard of care in RHD-AF
Evidence to Practice (@evi2prac) 's Twitter Profile Photo
Evidence to Practice
@evi2prac

3 years ago

Join us at our annual Symposium to discuss the latest topical and developing areas in cardiology! Tickets are going fast so register today.

Join us at our annual Symposium to discuss the latest topical and developing areas in cardiology! Tickets are going fast so register today.
The Asia Pacific Cardiometabolic Consortium (@the_apcmc) 's Twitter Profile Photo
The Asia Pacific Cardiometabolic Consortium
@the_apcmc

3 years ago

This Thursday, 16th March at 8.00pm AEDT via Asian Pacific Society of Cardiology Steve Nicholls will summarise the results from the CLEAR Outcomes trial. Join Steve and our panel as we discuss this important trial and the new option it presents for patients with statin intolerance.

This Thursday, 16th March at 8.00pm AEDT via <a href="/apsc_office/">Asian Pacific Society of Cardiology</a> <a href="/ProfSNicholls/">Steve Nicholls</a> will summarise the results from the CLEAR Outcomes trial. Join Steve and our panel as we discuss this important trial and the new option it presents for patients with statin intolerance.
The Asia Pacific Cardiometabolic Consortium (@the_apcmc) 's Twitter Profile Photo
The Asia Pacific Cardiometabolic Consortium
@the_apcmc

a year ago

Congratulations to our member Wann Jia Loh for hosting a Lp(a) #Awareness Day in conjunction with Changi General Hospital (CGH). Her goal was to 'unpack the who, what, why and how's of #lipoprotein(a).' Find out more information about Dr Wann’s initiative apcmc.net/education/

Congratulations to our member <a href="/WannJiaLoh/">Wann Jia Loh</a> for hosting a Lp(a) #Awareness Day in conjunction with Changi General Hospital (CGH). Her goal was to 'unpack the who, what, why and how's of #lipoprotein(a).' Find out more information about Dr Wann’s initiative apcmc.net/education/